Valganciclovir to Reduce T Cell Activation in HIV Infection

Investigator: Peter Hunt, MD
Sponsor: Roche Laboratories

Location(s): United States


The purpose of this study is to determine whether treatment with valganciclovir decreases T cell activation levels among HIV-infected patients with asymptomatic cytomegalovirus (CMV) co-infection, potentially improving immune responses to antiretroviral therapy.